Compare Adaptive Biotechnologies Corp (ADPT) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Davita Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.31 (market cap $4.04B), while Davita Inc trades at $181 (market cap $11.38B). The key difference: Davita Inc is far larger — about 2.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | DVA | |
|---|---|---|
Market Cap | $4.04B | $11.38B |
Sector | Health | Health |
52-Week High | $25.45 | $240.96 |
52-Week Low | $12.30 | $103.87 |
Enterprise Value | $4.10B | $24.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.
The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
